IL2 and chronic kidney disease: Reduction in:-monocyte secretory activity [63,64,65,66];-TNF-α, IL-6, IL-1beta, monocyte-1 chemoattractant protein, and CRP [64,65,66];-secretion of TNF-α by human primary monocytes and THP-1 cells [70];-serum CRP concentration in humans [67];-IL-2 and prevents the unwanted T-cell stimulation [67];-inhibits TGF-β1 release in patients with chronic kidney disease [69].No significant effect on:-IL-4, IL-13, and CRP [68].Increase in:-IL-10 concentration [66,68].